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A B S T R A C T
Interleukin (IL)-12 is a multifunctional cytokine acting as a key regulator of cell-mediated immune
responses through the differentiation of naı¨ve CD4+ T cells into type 1 helper T cells (Th1) producing
interferon-g. As our knowledge of IL-12 family members is rapidly growing, it will be important to
specify their involvement in the regulation of mycobacterial infection. This article is a review of the
current knowledge regarding the functions of the IL-12 family cytokines in the immune host defense
system against mycobacteria. Speciﬁcally, this review aims to describe recent scientiﬁc evidence
concerning the protective role of some members of the IL-12 family cytokines for the control of
mycobacterial infection, as well as to summarize knowledge of the potential use of the IL-12 family
members as potent adjuvants in the prevention and treatment of mycobacterial infectious diseases. In
addition, recent data supporting the importance of the IL-12 family members in mycobacterial diseases
in relation to Th17 function are discussed. This examination will help to improve our understanding of
the immune response to mycobacterial infection and also improve vaccine design and immunother-
apeutic intervention against tuberculosis.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Mycobacterium tuberculosis continues to be a leading cause of
human deaths due to an infectious agent.1 This problem is further
complicated by the association of tuberculosis with HIV/AIDS, by
the emergence of multidrug-resistant strains of M. tuberculosis,2
and by the variable efﬁciency of protection offered by vaccination
with Mycobacterium bovis bacillus Calmette–Gue´rin (BCG), the
only vaccine currently in use against tuberculosis.3,4 Therefore,
there is an urgent need to develop new therapeutics to control
human tuberculosis infection.
Protective immunity against mycobacteria is associated with
antigen presentation by the antigen-presenting cells (APC) to T
cells.5 After infection with the mycobacteria, APC acquire the
ability to stimulate type 1 CD4+ T helper cells (Th1), as well as the
secretion of cytokines, such as interleukin (IL)-12 and interferon
(IFN)-g.6 IL-12was independently discovered in 1989 by Trinchieri
et al.7 (termed ‘natural killer-stimulating factor’) and in 1990 by
Gately et al.8 (termed ‘cytotoxic lymphocyte maturation factor’).
For over a decade, IL-12 has been recognized as an important* Tel.: +52 5 729 60 00 ext. 62499; fax: +52 5 729 60 00x46211.
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been reported that the IL-12 cytokine family, which is evolutio-
narily linked to the IL-6 cytokine superfamily, is composed of IL-12,
IL-23, IL-27, and the newly identiﬁed IL-35.9–11 The current
literature indicates that IL-12 is part of a family of heterodimeric
cytokines that comprises: IL-12p70, which is a heterodimeric
cytokine composed of the p35 and p40 subunits (p35/p40); IL-23,
which shares the p40 chain with IL-12, but this subunit is
associated with a new protein, termed p19 chain (p19/p40); IL-27,
which is a heterodimeric cytokine composed of the Epstein–Barr
virus (EBV)-induced molecule 3 that associates with the IL-27 p28
chain (EBI-3/p28);12,13 and IL-35, which is composed of p35 and
EBI-3.11 Similar to IL-12, IL-23 and IL-27 are produced predomi-
nantly by macrophages and dendritic cells.9 In this context, it has
been demonstrated that IL-12p40, a component of IL-12p70 and IL-
23, can be secreted as a homodimer (IL-12p80) and as a monomer
(IL-12p40). Furthermore, it has been reported that IL-12p40 is
secreted at a 10–20-fold excess by stimulated human cells.14
Importantly, it has been reported that the IL-12 family cytokines
comprise 27 ligands and 34 receptor chains, and that the biological
functions of the IL-12 family cytokines are mediated by their
receptors.15 The subunits composing the receptors belong to the
gp130 subgroup. The IL-12 receptor is formed by the association of
the IL12Rb1 and b2 chains, which are expressed on humanses. Published by Elsevier Ltd. All rights reserved.
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activates the JAK-STAT signaling pathway, with STAT4 being the
predominant mediator of T cell responses activated by IL-12.16
Furthermore, Nagayama et al.,17 showed that stimulating human
dendritic cells with IL-12p70 results in a pattern of tyrosine
phosphorylation of intracellular protein distinct from that seen in T
cells treated with IL-12p70. The receptor for IL-23 is composed of
the IL-12Rb1 chain and another subunit termed IL-23R. The IL-27
receptor is composed of the IL27Ra subunit and gp130.16,18 At
present, the IL-35 receptor is still unknown. However, it is possible
that IL-35 will signal through the pairing of known receptor chains
utilized by the IL-12 cytokine family, since the p35 subunit of IL-12
binds to IL-12Rb2 to initiate signaling. The main functions of the
IL-12 family members in the immune response to mycobacterial
infection, the molecular basis for the effects, and the therapeutic
implication of IL-12 cytokine family in mycobacterial diseases are
discussed in this review.
2. Function of the IL-12 cytokine family
The biological functions of IL-12 are pivotal in both innate
resistance and adaptive immunity through activation of the JAK-
STAT signaling pathway, because it induces IFN-g production from
CD4+ T cells, natural killer (NK) cells, and NKT cells in the early
phases of the immune response,19,20 and induces the differentia-
tion of CD4+ T cells in Th1 effectors, relevant in protection against
bacterial infection.13 A protective role for the Th1 response
generated by IL-12/IL-23 has been suggested based on Mendelian
susceptibility to mycobacterial and other infectious diseases in
children with genetic defects of the IL-12/23–IFN-g circuit.21
Furthermore, Metzger et al.,22 showed that IL-12 induces a switch
in immunoglobulin isotypes by acting on B cells both directly and
indirectly via T-cell-derived IFN-g, resulting in enhanced produc-
tion of IgG2a antibodies and inhibition of IgE and IgG1 synthesis.
More recently, data from Curtsinger et al., suggest an involvement
of IL-12 as a third signal for CD8+ T cell differentiation.23 Yoo
et al.,24 have found that IL-12 serves as an important factor in the
reactivation and survival of memory CD4+ T cells. In addition, the
role of IL-12p40 as an antagonist of IL-12p70 biological activity as a
result of binding to the b1 subunit of the common IL-12 receptor
has been delineated.25,26 However, this mechanism may act
primarily in mouse cells and not in human cells, due to the low
afﬁnity of the human p40 homodimer for the IL-12 receptor. IL-
12p40 also inhibits IL-23-mediated functions.27 In contrast, it has
been demonstrated that the IL-12p40 cytokine can have agonist
activity in initiating the immune response.28 In this regard, it has
been demonstrated that IL-12p40 may act as a chemotactic
molecule for macrophages.29 Moreover, it has been acknowledged
that IL-12p40 is required for dendritic cell migration after M.
tuberculosis infection.30 More recently, data from Henry et al., have
indicated that this biological function of IL-12p40 correlates with
increased production of the chemokines CCL1 and CCL17,
suggesting that a main mechanism through which IL-12 augments
cellular activation is by facilitating chemokine production.31
At present, it has been reported that production of IL-12 by cells
requires CD40L–CD40 interaction.32,33 Furthermore, recent evi-
dence indicates that optimal IL-12, IL-23, and IL-27 production by
cells is through toll-like receptors (TLRs).34 In this regard, it has
been demonstrated that mice lacking the major adaptor protein
MyD88 (myeloid differentiation factor 88), required for TLR
signaling, are highly susceptible to M. tuberculosis infection.35
More recently, data from Wirtz et al., have indicated that EBI-3 is
strongly induced by TLR2, TLR4, and TLR9 stimulation.36 In
addition, it has been shown that following TLR stimulation,
nuclear factor-kappa B (NF-kB) complexes bind to a promoter
region of the EBI-3 gene and that MyD88 is required for inductionof EBI-3 downstream of TLR stimulation. Importantly, it has been
reported that mycobacterial DNA triggers the production of IL-
12p40 via TLRs.37 Moreover, recent results have demonstrated that
the M. tuberculosis LprA protein is an agonist of TLR2 that initiates
IL-12p40 secretion.38
Previous studies have indicated that human dendritic cells
produce IL-23 in a TLR2-dependent manner,39 and that IL-23 is an
activator of STAT4 and an inducer of IFN-g production in human T
cells.40 Oppmann et al.,41 have found that IL-23 enhances the
responses of memory T cells. In addition, the current literature
indicates that IL-23 is implicated in T-cell-dependent inﬂamma-
tory responses, since IL-23-deﬁcient mice have reduced antigen-
speciﬁc inﬂammatory responses.42,43 More recently, mouse
studies have demonstrated that IL-23 promotes differentiation
of Th17 cells, a new CD4+ T cell subset secreting IL-17.44,45
However, it has been demonstrated that IL-23 is not involved in the
early differentiation of naı¨ve CD4+ T cells into Th17 cells, since the
development of IL-17-producing effectors in a primary response in
vitro was relatively undiminished under conditions of IL-23
deﬁciency, and Th17 development was not enhanced by the
addition of exogenous IL-23.46–48 It is important to consider that
other cytokines, such as IL-6, are crucial to the differentiation
process of Th17 cells, since IL-6 acts promoting IL-23 receptor
(Il23r) expression, favoring Th17 cell differentiation.49,50 In
addition, it has been shown that IL-23 increases IFN-g production
by CD4+ T cells, but this effect is far less potent than that exerted by
IL-12p70; these comparative analyses have highlighted the
different roles of the IL-12 family cytokines in the developmental
pathways that promote the differentiation of CD4+ T cells.51
The current literature indicates that IL-27 is a cytokine with
complex roles in the control of innate and adaptive immune
responses.52,53 Recent studies have demonstrated that IL-27
antagonizes the development of Th17-cell responses during
inﬂammation in the central nervous system,54–56 and that IL-27-
mediated Th17 suppression depends on STAT1 activity.57 In
addition, it has also been demonstrated that IL-27 limits IL-2
production during Th1 differentiation.58 In contrast, it has been
demonstrated that IL-27 neutralization protects mice against
lethal septic peritonitis,59 and that can exert effects in the priming
of Th1 CD4+ T cell responses by inducing STAT1-dependent
expression of the transcription factor T-bet in naı¨ve CD4+ T cells,
leading to up-regulation of IL-12Rb2 and IFN-g synthesis.60,61 It
has also been demonstrated that IL-27 has contrasting biological
effects also at the level of T-cell proliferation.62 In fact, the current
literature indicates that IL-27 stimulates STAT1 and STAT3-
dependent T-cell proliferation,63,64 and that other STATs including
STAT4 and STAT5 are also phosphorylated in response to IL-27
stimulation.65 However, it has also been demonstrated that the
absence of the IL-27 receptor results in enhanced CD4+ T-cell
proliferation.59 Therapeutic implications of the anti-inﬂammatory
and immunosuppressive effects of IL-27 have also been shown in
regard to its pro-inﬂammatory or IFN-g-inducing properties.65 In
addition, in vivo blockade of IL-27 by soluble IL-27 receptor fusion
protein has been shown to result in increased survival of mice in a
septic peritonitis model.59
On the other hand, althoughmany of the biological effects of IL-
35 are still being elucidated, it is well known that IL-35 can
suppress naı¨ve CD4+ T cells, and that loss of IL-35 expression
results in the reduced in vivo suppressive capacity of CD4+ CD25+
forkhead box protein 3 (Foxp3)+ regulatory T cells (Tregs).66 In
addition, it has been acknowledged that IL-35 is expressed by
resting and activated Tregs.67 Furthermore, it has been suggested
that IL-35 can suppress in vivo Th17 development and ameliorate
collagen-induced arthritis.68 Importantly, a number of studies
have compared the relative susceptibility of p35 /mice. In this
context, it has been demonstrated that p35/mice resisted up to
Figure 1. Key features of IL-12 family members and their effects in the cellular
response to mycobacterial infectious diseases. Mycobacterial infections induce
macrophage/DC to produce IL-12p40, which promotes activation and migration of
mycobacteria-infected DCs. Development of Th1 cells is regulated by Treg. IL-
12p70, which shares homology with IL-23 and IL-27, promotes Th1 differentiation
and proliferation from naı¨ve T cells. The presence of IL-23 from activated DCs at an
early stage of mycobacterial infection results in enhancement of Th1 responses and
induction of protective T cells, and this production is further increased by IFN-g. IL-
23 is critically involved in the induction and function of the Th17 cells, and directs
the differentiation of naı¨ve T cells in Th17 cells. In addition, mycobacteria induce an
IL-17-producing (T cell receptor) TCRgd T cell population, which is important to
modulate granuloma formation and the control of mycobacterial growth. The
enhancement of Th1 response and induction of homing of effector Th1 cells into
infected organs results in a reduced mycobacterial burden. DC, dendritic cell; Th, T
helper; Treg, T regulatory cell.
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monocytogenes to an even greater degree than wild-type mice.69 In
M. tuberculosis infection, p35 / mice exhibit antigen-speciﬁc
responses far superior to those observed in p40 / mice;
however, neither were as capable of controlling the infection as
wild-type mice.70 In M. bovis infection, p35 / mice failed to
control infection, and treatment of mice with an IL-23 p19-speciﬁc
neutralizing antibody had no effect on M. bovis clearance,
indicating that IL-23 is not required for control of M. bovis
infection.71 In the remainder of this review, the discussion will
highlight the discoveries that have led to our current under-
standing of the biology of IL-12, IL-23, IL-27, and IL-35 in the
context of their role in resistance to mycobacterial infection.
3. Role of the IL-12 cytokine family in the control of cellular
immunity against mycobacterial infection
The current literature indicates that the importance of the IL-12
cytokine family in immunity against mycobacteria has been
proved by the fact that the absence of IL-12p40 or the IL-12Rb1 has
an important impact on the incidence of tuberculosis.21,70 In this
context, a role for IL-12p40 as an inducer of dendritic cellmigration
in the periphery to mycobacterial challenge has been demon-
strated.30 These data are supported by a publication that
demonstrated that dendritic cells expressing IL-12p40 are more
efﬁcient at migrating to the draining lymph node and stimulating
T-cell responses than are dendritic cells that are not producing IL-
12p40.72 Furthermore, Holscher et al.73 showed that during
infection with the attenuated M. bovis BCG vaccine, the delivery
of rIL-12p80 to IL-12p40-deﬁcient mice restores delayed type
hypersensitivity and antibacterial responses to the level seen in IL-
12p35-deﬁcient mice. More recently, data from Khader et al., have
indicated that IL-23 compensates for the absence of IL-12p70 and
that this IL-12 cytokine family member is essential for the IL-17
response during tuberculosis.74 This observationwas supported by
the fact that the continuous presence of IL-12 is needed for
maintenance of pulmonary Th1 effector function in chronic
tuberculosis.75 Previous studies have indicated that in M.
tuberculosis infection, clearance is elicited by IFN-g-producing T
cells. Furthermore, in this mycobacterial infection, p35 / mice
exhibited antigen-speciﬁc immune responses however, thesemice
were not as able to control the infection as wild-type mice.70
Moreover, vaccination elicits a protective response in wild-type
and p35 / mice, characterized by increased secretion of IFN-g
and IL-17.76 At present, it has been reported that in patients with
Mendelian susceptibility to mycobacterial disease, the disease is
caused as a result of IL-12b1 and IL-12p40 deﬁciency.21
Furthermore, Feinberg et al.,77 have shown that M. bovis BCG
triggers the IL-12/IFN-g axis by the NF-kB essential modulator
(NEMO) gene. More recently, data from Filipe-Santos et al., have
indicated the important role of NEMO/NF-kB-mediated induction
of IL-12 in immune protection against mycobacteria.78
At present, the importance of IL-23 in protective immunity
against mycobacterial infection has been demonstrated from the
analysis of IL-23-deﬁcient mice. In this context, it has been shown
that IL-12/IL-23-deﬁcient mice are more susceptible to the
infection than IL-12-deﬁcient mice.70 However, recent results
have indicated that IL-23-deﬁcient mice show normal protective
immunity to M. tuberculosis infection.74 These contradictory data
can be explained by suppression of Th17 development by IFN-g.79
It has also been demonstrated that IL-23 gene delivery increases
cellular immunity and controls growth of mycobacteria in the
lung.80 Recent results indicate that the induction of IL-17 cells is
very signiﬁcant duringmycobacterial infection,81–83 and that Th17
cells may be important in protection against M. tuberculosis
infection.76 Th17 cells may play an indirect role in M. tuberculosisinfection, as it has been demonstrated that Th17 memory cells
induced by a novel tuberculosis vaccine initiate recruitment of Th1
cells to the lung by upregulating the chemokines CXCL9, CXCL10,
and CXCL11.76 IL-17may also trigger recruitment of neutrophils to
the lung and facilitate granuloma formation.76 Recent results have
further clariﬁed that DNA vaccines expressing either IL-12 or IL-23
can reconstitute proliferation, IFN-g responses, and partially
restore protective immunity to mycobacteria infection upon
vaccination.84–87 Furthermore, Okada et al.,88 have shown that
the use of IL-12 as an adjuvant with DNA vaccine has resulted in
improved protection relative to BCG in the cynomolgus monkey
model. To improve upon current vaccines against tuberculosis, a
recent work demonstrated signiﬁcantly improved protection with
the use of IL-12-encapsulated microspheres delivered with a
monophosphoryl lipid A, saponin-containing adjuvant in tubercu-
losis subunit vaccination.89 Furthermore, the requirement for IL-23
in the generation of a lung-resident IL-17 producing T cell memory
population, which is important for vaccine-induced protective
immunity against mycobacterial infection, has also been shown.76
In contrast, recent studies have demonstrated that the absence of
Table 1
Major actions of IL-12 family members relevant to mycobacterial infection
Cytokine Major actions References
IL-12p40 DC activation and migration 30, 70
IL-12p70 Induction of Th1 responses 74, 75
IL-23 Induction of Th1 responses 80, 83, 84, 85
Th17 polarization and proliferation 76, 82, 93
IL-27 Th1 cell proliferation 90, 91, 92
DC, dendritic cell; Th, T helper; Treg, T regulatory cell.
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mycobacterial infection are not limited.71 These contradictory data
can be explained by the fact that in this study a live vaccine rather
than a subunit vaccine in a systemic challenge model was used.
Taken together, these data indicate a signiﬁcant role of IL-12 and
IL-23 for the protective role of the Th1 responses to mycobacteria
(see Figure 1 and Table 1).
With regard to the role of IL-27 in the immune response against
mycobacterial infections, the improved control of mycobacterial
growth in the lungs of mice lacking IL-27 receptor signaling has
also been demonstrated.90,91 Holscher et al.,91 reported that this
increased control of mycobacterial burden is correlated with
increased inﬂammatory cytokine responses in the lung. More
recently, it was acknowledged that IL-27 negatively regulates the
development of Th17 type cells during chronic inﬂammation.53 It
has been demonstrated that M. tuberculosis infection induces an
antigen-speciﬁc Th17 response,74 and that these cells share
developmental and functional relationship with Foxp3-expressing
Treg cells, which serve to controlmycobacterial growth.92 Lockhart
et al.93 found that M. tuberculosis infection induces an IL-17-
producing gd T cell population, which is important to modulate
granuloma formation. In addition, D’Souza et al.94 demonstrated
an anti-inﬂammatory role for gd T lymphocytes in acquired
immunity to M. tuberculosis, suggesting that these cells may
provide a mechanism by which IL-17 moderates inﬂammation in
tuberculosis (see Figure 1).
4. Concluding remarks
In the light of the epidemic of tuberculosis in populations co-
infected with HIV, the failure of BCG to protect against disease, and
the recent emergence of multidrug-resistant strains of M.
tuberculosis, new approaches for the treatment of tuberculosis
are urgently needed. The fact that the absence of IL-12p40 or the IL-
12Rb1 has a greater impact on the incidence of tuberculosis, and
that one of the major actions of the IL-12 family members is the
induction of Th1 responses, a protective role for these responses
could favor the tuberculosis control process, and is crucial for
vaccine-induced protection against tuberculosis. In this context,
the role of IL-12 family cytokines to mediate the activation of
dendritic cells, to promote macrophage migration, and to
participate for the optimal IFN-g T cell response, make this family
of cytokines potential candidates for the treatment of human
tuberculosis. At present, it is critical to reassess the involvement of
the IL-12/IL-23 balance in the control of mycobacterial infections,
since current available data indicate that this balance appears to be
important for the differentiation of Th17 cells in mycobacterial
diseases. Further insight into the biological role of IL-12/Th1, IL-23/
Th17, IL-27 and IL-35/Treg pathways in mycobacterial infection is
a priority for futuremycobacteria research. In addition, therapeutic
applications of the anti-inﬂammatory effects of IL-27 have also
been shown in various experimental settings. In fact, the more
effective application of IL-12 family members as therapeutic
agents with considerable potential in patients with tuberculosis
should be evaluated. An important issue to be elucidated is the
clear dissection of the anti-inﬂammatory signal pathways down-stream of the IL-27R. Establishment of antagonistic as well as
agonistic anti-IL-27R antibodies and the development of engi-
neered recombinant IL-27 have important implications for the
design of new therapeutic approaches in mycobacterial infection.
Moreover, a further promising area of investigation stems from the
emerging knowledge of newly discovered IL-12 family members.
This could lead to a more durable and effective immune response
against mycobacterial infection, and hence, greatly improve the
therapeutic efﬁcacy of IL-12-based treatments. Finally, to establish
an effective method for the use of IL-12 family members, we may
need further information with regard to the situations in which IL-
12p40, IL-27 and IL-35 exert their inhibitory biological functions,
how production of IL-12 family members is controlled, and the
relative potency of these cytokines as immunomodulators.
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